Cell Kinetics

Clinical Oncology

Volumn 19, Issue 6, 2007, Pages 370-384

  Wilson, G D ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Accelerated fractionation; cell cycle; cell kinetics; proliferation; radiosensitivity; repopulation

Indexed keywords

BROXURIDINE;

ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE; CELL DAMAGE; CELL HYPOXIA; CELL KINETICS; CELL PROLIFERATION; CELL REGENERATION; CELLULAR DISTRIBUTION; CLINICAL PRACTICE; DISEASE FREE SURVIVAL; FIBROSIS; FLOW CYTOMETRY; HISTORY OF MEDICINE; HUMAN; MUCOSA INFLAMMATION; OROPHARYNX CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOBIOLOGY; RADIOSENSITIVITY; REOXYGENATION; TREATMENT OUTCOME;

ANIMALS; CELL CYCLE; CELL DEATH; CELL HYPOXIA; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; KINETICS; NEOPLASMS; RADIATION TOLERANCE; RADIOBIOLOGY; TUMOR CELLS, CULTURED;

EID: 34347261036     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.02.015     Document Type: Article

References (128)

1. 32P as demonstrated by autoradiographs. Exp Cell Res 2 (1951) 178-187
2. Howard A., and Pelc S.R. Synthesis of deoxyribonucleic acid in normal and irradiated cells and its relation to chromosome breakage. Heredity 6 Suppl. (1953) 261-273
3. Mottram J.C., Scott G.M., and Russ S. Effects of beta-rays upon division and growth of cancer cells. Proc R Soc B 100 (1926) 326-334
4. Yamada M., and Puck T.T. Action of radiation on mammalian cells. IV. Reversible mitotic lag in the S3 HeLa cell produced by low doses of X-rays. Proc Natl Acad Sci U S A 47 (1961) 1181-1191
5. Terasima T., and Tolmach L.J. X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells. Science 140 (1963) 490-492
6. Terasima T., and Tolmach L.J. Variations in several responses of HeLa cells to x-irradiation during the division cycle. Biophys J 3 (1963) 11-33
7. Lamerton L.F., and Steel G.G. Cell population kinetics in normal and malignant tissues. Prog Biophys Mol Biol 18 (1968) 245-283
8. Steel G.G. The growth kinetics of tumors in relation to their therapeutic response. Laryngoscope 85 (1975) 359-370
9. Tubiana M., Frindel E., and Malaise E. The application of radiobiologic knowledge and cellular kinetics to radiation therapy. Am J Roentgenol Radium Ther Nucl Med 102 (1968) 822-830
10. Brown J.M., and Wilson G. Apoptosis genes and resistance to cancer therapy: what does the experimental and clinical data tell us?. Cancer Biol Ther 2 (2003) 477-490
11. Dewey W.C., Ling C.C., and Meyn R.E. Radiation-induced apoptosis: relevance to radiotherapy. Int J Radiat Oncol Biol Phys 33 (1995) 781-796
12. Stewart F.A., and van der Kogel A.J. Proliferative and cellular organization of normal tissues. In: Steel G.G. (Ed). Basic Clinical Radiobiology. 3rd edn (2002), Arnold, New York p. 23-29
13. Sonis S.T. The pathobiology of mucositis. Nat Rev Cancer 4 (2004) 277-284
14. O'Sullivan B., and Levin W. Late radiation-related fibrosis: pathogenesis, manifestations, and current management. Semin Radiat Oncol 13 (2003) 274-289
15. Spratt J.S., Heuser L., Kuhns J.G., et al. Association between the actual doubling times of primary breast cancer with histopathologic characteristics and Wolfe's parenchymal mammographic patterns. Cancer 47 (1981) 2265-2268
16. Tubiana M., Pejovic M.J., Renaud A., et al. Kinetic parameters and the course of the disease in breast cancer. Cancer 47 (1981) 937-943
17. Dische S., Saunders M., Barrett A., et al. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 44 (1997) 123-136
18. Trott K.R., and Kummermehr J. What is known about tumour proliferation rates to choose between accelerated fractionation or hyperfractionation?. Radiother Oncol 3 (1985) 1-9
19. Rew D.A., and Wilson G.D. Cell production rates in human tissues and tumours and their significance. Part II: clinical data. Eur J Surg Oncol 26 (2000) 405-417
20. Borre M., Hoyer M., Sorensen F.B., et al. Potential doubling time (TPOT) in adenocarcinoma of the prostate. Eur J Cancer 33 Suppl. 8 (1997) 33
21. Sinclair W.K. Cyclic X-ray responses in mammalian cells in vitro. Radiat Res 33 (1968) 620-643
22. Schneiderman M.H., and Schneiderman G.S. G2 cells: progression delay and survival. Radiat Res 98 (1984) 389-396
23. Schneiderman M.H., Schneiderman G.S., and Rusk C.M. A cell kinetic method for the mitotic selection of treated G2 cells. Cell Tissue Kinet 16 (1983) 41-49
24. Biade S., Stobbe C.C., and Chapman J.D. The intrinsic radiosensitivity of some human tumor cells throughout their cell cycles. Radiat Res 147 (1997) 416-421
25. Hill A.A., Wan F., Acheson D.K., et al. Lack of correlation between G1 arrest and radiation age-response in three synchronized human tumour cell lines. Int J Radiat Biol 75 (1999) 1395-1408
26. Rothkamm K., Kruger I., Thompson L.H., et al. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol 23 (2003) 5706-5715
27. Kao G.D., McKenna W.G., and Yen T.J. Detection of repair activity during the DNA damage-induced G2 delay in human cancer cells. Oncogene 20 (2001) 3486-3496
28. Xu B., Kim S.T., Lim D.S., et al. Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol Cell Biol 22 (2002) 1049-1059
29. Stobbe C.C., Park S.J., and Chapman J.D. The radiation hypersensitivity of cells at mitosis. Int J Radiat Biol 78 (2002) 1149-1157
30. Withers H.R. Cell cycle redistribution as a factor in multifraction irradiation. Radiology 114 (1975) 199-202
31. Hahn G.M. Cellular kinetics, cell cycles and cell killing. Biophysik 4 (1967) 1-14
32. Price L.A., Hill B.T., Calvert A.H., et al. Kinetically-based multiple drug treatment for advanced head and neck cancer. Br Med J 3 (1975) 10-11
33. Tannock I. Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep 62 (1978) 1117-1133
34. Steel G.G. Cell synchronization unfortunately may not benefit cancer therapy. Radiother Oncol 32 (1994) 95-97
35. Grant S., and Roberts J.D. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resist Updat 6 (2003) 15-26
36. Brizel D.M., Sibley G.S., Prosnitz L.R., et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38 (1997) 285-289
37. Evans S.M., and Koch C.J. Prognostic significance of tumor oxygenation in humans. Cancer Lett 195 (2003) 1-16
38. Fyles A.W., Milosevic M., Wong R., et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48 (1998) 149-156
39. Hockel M., Knoop C., Schlenger K., et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26 (1993) 45-50
40. Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77 (2005) 18-24
41. Vaupel P., Kelleher D.K., and Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28 (2001) 29-35
42. Thomlinson R.H., and Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9 (1955) 539-549
43. Hoskin P.J., Sibtain A., Daley F.M., et al. The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma. Radiother Oncol 72 (2004) 159-168
44. Ljungkvist A.S., Bussink J., Rijken P.F., et al. Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 54 (2002) 215-228
45. van Laarhoven H.W., Kaanders J.H., Lok J., et al. Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. Int J Radiat Oncol Biol Phys 64 (2006) 473-482
46. Vaupel P., Mayer A., and Hockel M. Tumor hypoxia and malignant progression. Meth Enzymol 381 (2004) 335-354
47. Scott O.C. Mathematical models of repopulation and reoxygenation in radiotherapy. Br J Radiol 63 (1990) 821-823
48. Hill R.P., Fyles W., Milosevic M., et al. Is there a relationship between repopulation and hypoxia/reoxygenation? Results from human carcinoma of the cervix. Int J Radiat Biol 79 (2003) 487-494
49. Kaanders J.H., Bussink J., and van der Kogel A.J. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 3 (2002) 728-737
50. Koukourakis M.I., Bentzen S.M., Giatromanolaki A., et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24 (2006) 727-735
51. Haustermans K.M., Hofland I., Van Poppel H., et al. Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997) 1067-1070
52. Movsas B., Chapman J.D., Hanlon A.L., et al. Hypoxia in human prostate carcinoma: an Eppendorf PO2 study. Am J Clin Oncol 24 (2001) 458-461
53. Parker C., Milosevic M., Toi A., et al. Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 750-757
54. Petersen C., Eicheler W., Frommel A., et al. Proliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol 79 (2003) 469-477
55. Petersen C., Zips D., Krause M., et al. Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. Int J Radiat Oncol Biol Phys 51 (2001) 483-493
56. Speke A.K., and Hill R.P. Repopulation kinetics during fractionated irradiation and the relationship to the potential doubling time, Tpot. Int J Radiat Oncol Biol Phys 31 (1995) 847-856
57. Tsang R.W., Fyles A.W., Li Y., et al. Tumor proliferation and apoptosis in human uterine cervix carcinoma I: correlations between variables. Radiother Oncol 50 (1999) 85-92
58. Ellis F. Dose, time and fractionation: a clinical hypothesis. Clin Radiol 20 (1969) 1-7
59. Hermens A.F., and Barendsen G.W. Changes of cell proliferation characteristics in a rat rhabdomyosarcoma before and after x-irradiation. Eur J Cancer 5 (1969) 173-189
60. Barendsen G.W. Experimental data on cellular recovery and repopulation in tumours after fractionated irradiation. Radiol Clin Biol 39 (1970) 374-375
61. Baumann M., Dorr W., Petersen C., et al. Repopulation during fractionated radiotherapy: much has been learned, even more is open. Int J Radiat Biol 79 (2003) 465-467
62. Bentzen S.M. Repopulation in radiation oncology: perspectives of clinical research. Int J Radiat Biol 79 (2003) 581-585
63. Denekamp J. Changes in the rate of repopulation during multifraction irradiation of mouse skin. Br J Radiol 46 (1973) 381-387
64. Denekamp J. Cell kinetics and radiation biology. Int J Radiat Biol Relat Stud Phys Chem Med 49 (1986) 357-380
65. Dorr W., Emmendorfer H., Haide E., et al. Proliferation equivalent of 'accelerated repopulation' in mouse oral mucosa. Int J Radiat Biol 66 (1994) 157-167
66. Fowler J.F. Rapid repopulation in radiotherapy: a debate on mechanism. The phantom of tumor treatment - continually rapid proliferation unmasked. Radiother Oncol 22 (1991) 156-158
67. Kinsella T.J., Gould M.N., Mulcahy R.T., et al. Keynote address: Integration of cytostatic agents and radiation therapy: a different approach to "proliferating" human tumors. Int J Radiat Oncol Biol Phys 20 (1991) 295-302
68. Kummermehr J., Dorr W., and Trott K.R. Kinetics of accelerated repopulation in normal and malignant squamous epithelia during fractionated radiotherapy. Br J Radiol 24 Suppl. (1992) 193-199
69. Maciejewski B., Withers H.R., Taylor J.M., et al. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation. Int J Radiat Oncol Biol Phys 16 (1989) 831-843
70. Thames H.D., Bentzen S.M., Turesson I., et al. Time-dose factors in radiotherapy: a review of the human data. Radiother Oncol 19 (1990) 219-235
71. Trott K.R. Cell repopulation and overall treatment time. Int J Radiat Oncol Biol Phys 19 (1990) 1071-1075
72. Trott K.R. Perspectives of experimental research on repopulation during radiotherapy. Int J Radiat Biol 79 (2003) 577-580
73. Trott K.R., and Kummermehr J. Rapid repopulation in radiotherapy: a debate on mechanism. Accelerated repopulation in tumours and normal tissues. Radiother Oncol 22 (1991) 159-160
74. Withers H.R., Maciejewski B., Taylor J.M., et al. Accelerated repopulation in head and neck cancer. Front Radiat Ther Oncol 22 (1988) 105-110
75. Withers H.R., Taylor J.M., and Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27 (1988) 131-146
76. Fowler J.F. The first James Kirk memorial lecture. What next in fractionated radiotherapy?. Br J Cancer 6 Suppl. (1984) 285-300
77. Thames Jr. H.D., Peters L.J., Withers H.R., et al. Accelerated fractionation vs hyperfractionation: rationales for several treatments per day. Int J Radiat Oncol Biol Phys 9 (1983) 127-138
78. Withers H.R. Biological bases for modifying conventional fractionation regimens in radiotherapy. Strahlentherapie 160 (1984) 670-677
79. Begg A.C., McNally N.J., Shrieve D.C., et al. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 6 (1985) 620-626
80. Wilson G.D., McNally N.J., Dunphy E., et al. The labelling index of human and mouse tumours assessed by bromodeoxyuridine staining in vitro and in vivo and flow cytometry. Cytometry 6 (1985) 641-647
81. Saunders M.I., Dische S., Fowler J.F., et al. Radiotherapy employing three fractions on each of twelve consecutive days. Acta Oncol 27 (1988) 163-167
82. Withers HR. Biology of altered fractionation. Paper presented at the Progress in Radio-Oncology IV, Vienna, 1988.
83. Horiot J.C., Bontemps P., van den Bogaert W., et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 44 (1997) 111-121
84. Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48 (2000) 7-16
85. Bentzen S.M., and Thames H.D. Overall treatment time and tumor control dose for head and neck tumors: the dog leg revisited. Radiother Oncol 25 (1992) 143-144
86. Slevin N.J., Hendry J.H., Roberts S.A., et al. The effect of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapy. Radiother Oncol 24 (1992) 215-220
87. Fowler J.F. Potential for increasing the differential response between tumors and normal tissues: can proliferation rate be used?. Int J Radiat Oncol Biol Phys 12 (1986) 641-645
88. Fowler J.F. How worthwhile are short schedules in radiotherapy? A series of exploratory calculations. Radiother Oncol 18 (1990) 165-181
89. Bourhis J., Overgaard J., Audry H., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368 (2006) 843-854
90. Bourhis J., Lapeyre M., Tortochaux J., et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol 24 (2006) 2873-2878
91. Overgaard J., Alsner J., Eriksen J., et al. Importance of overall treatment time for the response to radiotherapy in patients with squamous cell carcinoma of the head and neck. Rays 25 (2000) 313-319
92. Skladowski K., Maciejewski B., Golen M., et al. Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial. Int J Radiat Oncol Biol Phys 66 (2006) 706-713
93. Dolbeare F., Gratzner H., Pallavicini M.G., et al. Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc Natl Acad Sci U S A 80 (1983) 5573-5577
94. Gratzner H.G. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science 218 (1982) 474-475
95. Steel G.G. Growth kinetics of tumours (1977), Clarendon Press, Oxford
96. Rew D.A., and Wilson G.D. Cell production rates in human tissues and tumours and their significance. Part 1: an introduction to the techniques of measurement and their limitations. Eur J Surg Oncol 26 (2000) 227-238
97. Bourhis J., Dendale R., Hill C., et al. Potential doubling time and clinical outcome in head and neck squamous cell carcinoma treated with 70 Gy in 7 weeks. Int J Radiat Oncol Biol Phys 35 (1996) 471-476
98. Dobrowsky W., Dobrowsky E., and Wilson G.D. In vivo cell kinetic measurements in a randomized trial of continuous hyperfractionated accelerated radiotherapy with or without mitomycin C in head-and-neck cancer. Int J Radiat Oncol Biol Phys 55 (2003) 576-582
99. Wilson G.D. Cell kinetic studies using a monoclonal antibody to bromodeoxyuridine. Methods Mol Biol 80 (1998) 255-266
100. Wilson G.D., Paschoud N., Pavy J.J., et al. Reproducibility of measurements of potential doubling time of tumour cells in the multicentre National Cancer Institute protocol T92-0045. Br J Cancer 79 (1999) 323-332
101. Zackrisson B., Gustafsson H., Stenling R., et al. Predictive value of potential doubling time in head and neck cancer patients treated by conventional radiotherapy. Int J Radiat Oncol Biol Phys 38 (1997) 677-683
102. Bolger B.S., Cooke T.G., Symonds R.P., et al. Measurement of cell kinetics in cervical tumours using bromodeoxyuridine. Br J Cancer 68 (1993) 166-171
103. Terry N.H., Meistrich M.L., Roubein L.D., et al. Cellular kinetics in rectal cancer. Br J Cancer 72 (1995) 435-441
104. Haustermans K., Vanuytsel L., Geboes K., et al. In vivo cell kinetic measurements in human oesophageal cancer: what can be learned from multiple biopsies?. Eur J Cancer 30A (1994) 1787-1791
105. Struikmans H., Rutgers D.H., Jansen G.H., et al. Prognostic relevance of cell proliferation markers and DNA-ploidy in gliomas. Acta Neurochir 140 (1998) 140-147
106. Rew D.A., Campbell I.D., Taylor I., et al. Proliferation indices of invasive breast carcinomas after in vivo 5-bromo-2′-deoxyuridine labelling: a flow cytometric study of 75 tumours. Br J Surg 79 (1992) 335-339
107. Wilson G.D. Limitations of the BUdR technique for measurement of tumour proliferation. In: Beck-Bornholdt H.P. (Ed). Current topics in clinical radiobiology of tumours (1993), Springer, Berlin 28-43
108. Wilson M.S., West C.M., Wilson G.D., et al. Intra-tumoral heterogeneity of tumour potential doubling times (Tpot) in colorectal cancer. Br J Cancer 68 (1993) 501-506
109. Bennett M.H., Wilson G.D., Dische S., et al. Tumour proliferation assessed by combined histological and flow cytometric analysis: implications for therapy in squamous cell carcinoma in the head and neck. Br J Cancer 65 (1992) 870-878
110. Begg A.C., Hofland I., Moonen L., et al. The predictive value of cell kinetic measurements in a European trial of accelerated fractionation in advanced head and neck tumors: an interim report. Int J Radiat Oncol Biol Phys 19 (1990) 1449-1453
111. Haustermans K., Hofland I., Pottie G., et al. Can measurements of potential doubling time (Tpot) be compared between laboratories? A quality control study. Cytometry 19 (1995) 154-163
112. Tsang R.W., Fyles A.W., Kirkbride P., et al. Proliferation measurements with flow cytometry Tpot in cancer of the uterine cervix: correlation between two laboratories and preliminary clinical results. Int J Radiat Oncol Biol Phys 32 (1995) 1319-1329
113. Wilson M.S., West C.M., Wilson G.D., et al. An assessment of the reliability and reproducibility of measurement of potential doubling times (Tpot) in human colorectal cancers. Br J Cancer 67 (1993) 754-759
114. Awwad H.K., Khafagy Y., Barsoum M., et al. Accelerated versus conventional fractionation in the postoperative irradiation of locally advanced head and neck cancer: influence of tumour proliferation. Radiother Oncol 25 (1992) 261-266
115. Bourhis J., Wilson G., Wibault P., et al. In vivo measurement of the potential doubling time by flow cytometry in oropharyngeal cancer treated by conventional radiotherapy. Int J Radiat Oncol Biol Phys 26 (1993) 793-799
116. Corvo R., Giaretti W., Sanguineti G., et al. Potential doubling time in head and neck tumors treated by primary radiotherapy: preliminary evidence for a prognostic significance in local control. Int J Radiat Oncol Biol Phys 27 (1993) 1165-1172
117. Corvo R., Paoli G., Giaretti W., et al. Evidence of cell kinetics as predictive factor of response to radiotherapy alone or chemoradiotherapy in patients with advanced head and neck cancer. Int J Radiat Oncol Biol Phys 47 (2000) 57-63
118. Awwad H.K., Lotayef M., Shouman T., et al. Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation. Br J Cancer 86 (2002) 517-523
119. Begg A.C., Hofland I., Van Glabbeke M., et al. Predictive value of potential doubling time for radiotherapy of head and neck tumor patients: results from the EORTC cooperative trial 22851. Semin Radiat Oncol 2 (1992) 22-25
120. Eschwege F., Bourhis J., Girinski T., et al. Predictive assays of radiation response in patients with head and neck squamous cell carcinoma: a review of the Institute Gustave Roussy experience. Int J Radiat Oncol Biol Phys 39 (1997) 849-853
121. Hoyer M., Jorgensen K., Bundgaard T., et al. Lack of predictive value of potential doubling time and iododeoxyuridine labelling index in radiotherapy of squamous cell carcinoma of the head and neck. Radiother Oncol 46 (1998) 147-155
122. Struikmans H., Rutgers D.H., Hordijk G.J., et al. Prognostic significance of cell proliferation markers and DNA-ploidy in head and neck tumors. Int J Radiat Oncol Biol Phys 40 (1998) 27-34
123. Begg A.C., Haustermans K., Hart A.A., et al. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother Oncol 50 (1999) 13-23
124. Silvestrini R., Molinari R., Costa A., et al. Short-term variation in labeling index as a predictor of radiotherapy response in human oral cavity carcinoma. Int J Radiat Oncol Biol Phys 10 (1984) 965-970
125. Zackrisson B., Flygare P., Gustafsson H., et al. Cell kinetic changes in human squamous cell carcinomas during radiotherapy studied using the in vivo administration of two halogenated pyrimidines. Eur J Cancer 38 (2002) 1100-1106
126. Chao K.S. Functional imaging for early prediction of response to chemoradiotherapy: 3′-deoxy-3′-(18)F-fluorothymidine positron emission tomography - a clinical application model of esophageal cancer. Semin Oncol 33 Suppl. 11 (2006) 59-63
127. Pio B.S., Park C.K., Pietras R., et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8 (2006) 36-42
128. Shields A.F., Grierson J.R., Dohmen B.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4 (1998) 1334-1336